Smithkline Beecham Biologicals S.a.

Smithkline Biologicals, S.a.

Glaxosmithkline Biologicals Sa

Pierre Voet

Pierre Hauser

Clothilde Thiriart

Nathalie Marie-Josephe Claude Garcon-Johnson

Jan Poolman

Philippe Denoel

Joelle Thonnard

Moncef Mohamed Slaoui

Yves Lobet

Cornelis P Hollenberg

Pierre Desmons

Zbigniew A Janowicz

Nathalie Marie-Josephe Garcon-Johnson

Guy Dequesne

Christiane Feron

Nigel Harford

Armin J Merckelbach

Eric Jacobs

Teresa Cabezon

Martin Comberbach

Apolonia Rutgers

Georges Thiry

Francois-Xavier Jacques Berthet

Wilfried L Dalemans

Wilfred L J Dalemans

Moncef Slaoui

A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A combination vaccines including the vaccine formulation are also described.

Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A

A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination vaccines including the vaccine formulation are also described.

Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A

A composite particle comprising at least two polypeptides corresponding to all or part of a protein having the biological activity of one of the hepatitis B surface antigens, wherein the particle presents at least two antigenic determinants provided by the S-protein, preS2-protein or preS1-protein, said particle optionally further comprising host specific lipids. The invention also provides a modified hepatitis B surface antigen L protein which may be used alone or incorporated into such composite particles. A particular embodiment of the modified L protein (L*) comprises residues 12-52 followed by residues 133-145 followed by residues 175-400 of the L protein and a particular embodiment of a composite particle has the form (L*, S) where S is the S-protein of HBsAg. Improved hepatitis B vaccines may be prepared following expression of the above immunogens, especially in yeasts such as S. cerevisiae and Hansenula polymorpha.

Antigens and methods therefor

Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A

Growing community of inventors

Izel, Belgium

Pierre Voet